Robbins LLP Urges HIMS Stockholders with Large Losses to Contact the Firm for Information About the Class Action Pending Against Hims & Hers Health, Inc.

Associated Press

04-07-2025

SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Hims & Hers Health, Inc. (NYSE: HIMS) securities between April 29, 2025 and June 22, 2025. Hims operates a telehealth platform that connects consumers to licensed healthcare professionals.
For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at [phone].
The Allegations: Robbins LLP is Investigating Allegations that Hims & Hers Health, Inc. (HIMS) Deceptively Promoted and Sold Illegitimate Versions of Wegovy®
According to the complaint, on April 29, 2025, Hims announced a long-term collaboration with Novo Nordisk, starting with the immediate sale of 'a bundled offering of Novo Nordisk's FDA-approved Wegovy® on the Hims & Hers platform.' However, on June 23, 2025, Novo Nordisk issued a press release announcing that it was terminating its partnership with Hims, 'based on Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk.' On this news, the Company's share price fell $22.24, or 34.6%, to close at $41.98 per share on June 23, 2025.
Plaintiff alleges that during the class period, defendants failed to disclose to investors: (1) that Hims was engaged in the 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk;' and (2) that, as a result, there was a substantial risk that the Company's collaboration with Novo Nordisk would be terminated.
What Now: You may be eligible to participate in the class action against Hims & Hers Health, Inc. Shareholders who want to serve as lead plaintiff for the class must file a motion for lead plaintiff by August 25, 2025. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.
To be notified if a class action against Hims & Hers Health, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.